Mereo Biopharma Group Plc ADR’s filing revealed that its Chief Executive Officer Scots-Knight Denise unloaded Company’s shares for reported $0.25 million on Sep 13 ’24. In the deal valued at $4.22 per share,60,046 shares were sold. As a result of this transaction, Scots-Knight Denise now holds 808,921 shares worth roughly $2.31 million.
Then, Scots-Knight Denise sold 28,611 shares, generating $127,968 in total proceeds. Upon selling the shares at $4.47, the Chief Executive Officer now owns 868,967 shares.
Before that, Lewicki John A. sold 10,937 shares. Mereo Biopharma Group Plc ADR shares valued at $46,165 were divested by the Chief Scientific Officer at a price of $4.22 per share. As a result of the transaction, Lewicki John A. now holds 78,630 shares, worth roughly $0.22 million.
Jefferies initiated its Mereo Biopharma Group Plc ADR [MREO] rating to a Buy in a research note published on December 06, 2024; the price target was $7. A number of analysts have revised their coverage, including Robert W. Baird’s analysts, who began to cover the stock in mid June with a ‘”an Outperform”‘ rating. Cantor Fitzgerald started covering the stock on August 12, 2022. It rated MREO as “an Overweight”.
Price Performance Review of MREO
On Friday, Mereo Biopharma Group Plc ADR [NASDAQ:MREO] saw its stock fall -0.70% to $2.85. Over the last five days, the stock has lost -1.04%. Mereo Biopharma Group Plc ADR shares have fallen nearly -18.57% since the year began. Nevertheless, the stocks have fallen -20.39% over the past one year.
Levels Of Support And Resistance For MREO Stock
The 24-hour chart illustrates a support level at 2.79, which if violated will result in even more drops to 2.72. On the upside, there is a resistance level at 2.91. A further resistance level may holdings at 2.96. The Relative Strength Index (RSI) on the 14-day chart is 38.17, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.10, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 85.26%. Stochastics %K at 18.10% indicates the stock is a buying.
The most recent change occurred on May 05, 2021 when BTIG Research began covering the stock and recommended ‘”a Buy”‘ rating along with a $10 price target.
